<p>医疗保健领域继续是创新的热点，生物技术处于领先地位。从开创性的基因疗法到下一代癌症治疗，生物技术公司正在推动医学边界并改变患者护理。</p>
<p>今年已经见证了生物技术领域的重大进展。我们看到了成功的临床试验，针对改变生活的疗法的监管批准以及行业内的重大收购。例如，7 月 2 日，美国食品药品监督管理局（FDA）批准了礼来（纽约证券交易所：LLY）的新阿尔茨海默病药物，唐纳替普，市场上称为基舜拉。该药物专为早期阿尔茨海默病患者设计，据显示在 18 个月内相对于安慰剂减缓认知衰退 29%。</p>
<p>行业的增长势头预计将继续，受到投资者信心上升和对科学突破的不懈追求的推动。事实上，全球生物技术市场预计将从 2023 年的近 1.4 万亿美元增长到 2033 年的超过 4 万亿美元，复合年增长率（CAGR）为 11.8%。北美市场领先，受关键参与者、强大的研发和高医疗支出推动。</p>
<p>值得注意的是，iShares 生物技术交易所交易基金（纳斯达克：IBB）表现不佳，年初至今仅上涨 1%。这表明生物技术行业存在迎头赶上的潜力。现在，让我们重点介绍三家备受好评的生物技术股票，因其最近的监管批准、战略收购和授予专利而脱颖而出。</p>
<h2><strong>Biogen（BIIB）</strong></h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>图片来源：Pavel Kapysh / Shutterstock.com</p>
<p>榜首的生物技术股票是 Biogen（纳斯达克：BIIB），专注于复杂的神经系统和神经退行性疾病。该公司的产品线包括治疗多发性硬化症（MS）、脊髓性肌萎缩症、斑块性银屑病和阿尔茨海默病等疾病的治疗。</p>
<p>然而，Biogen 在 2024 年第一季度的业绩在 4 月底呈现出一幅复杂的画面。尽管总收入同比下降 7% 至 22.9 亿美元，但稀释每股收益增长 8% 至 3.67 美元。这标志着一个重要的里程碑，代表了 Biogen 多年来首次实现的每股收益增长。</p>
<p>Biogen 通过最近的监管批准加强了在两个关键治疗领域的存在。欧洲委员会授予了 Tofidence 的上市授权，这是一种参考罗氏希罗达治疗各种炎症性疾病的生物类似药。另外，Biogen 与 Eisai（柜台市场：ESAIY）的合作推出了 Leqembi（勒坎替普）在中国的上市。这是首个获批用于减缓阿尔茨海默病进展的治疗。</p>
<p>尽管出现这些积极发展，BIIB 股票今年迄今已下跌 10%。目前，Biogen 股票以合理的 14.3 倍未来收益和 3.5 倍销售额交易。分析师对 BIIB 的 12 个月价格目标为 285.60 美元，预示着 25% 的上涨潜力。</p>
<h2><strong>Incyte（INCY）</strong></h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>图片来源：Eyesonmilan / Shutterstock.com</p>
<p>生物制药公司 Incyte（纳斯达克：INCY）专注于开发新型小分子疗法，以满足肿瘤学和炎症性疾病领域的未满足医疗需求。Incyte 的产品组合包括几种高影响力药物，如 Jakafi、Pemazyre 和 Iclusig，针对骨髓纤维化、红细胞增多症和慢性髓细胞白血病。</p>
<p>Incyte 报告了 2024 年第一季度的强劲业绩，总收入同比增长 9% 至 8.81 亿美元。Jakafi，他们针对骨髓纤维化的核心产品，保持了强劲表现，净产品收入为 5.72 亿美元。净收入和稀释每股收益分别同比激增约 72% 至 1.453 亿美元和 64 美分。</p>
<p>Incyte 已完成对 Escient Pharmaceuticals 的收购，该公司专注于开发治疗系统性免疫和神经免疫疾病的新型治疗方法。这一举措预计将加强 Incyte 的炎症和自身免疫组合。</p>
<p>尽管业绩强劲，INCY 股票在 2024 年迄今已下跌超过 5%。Incyte 股票以有吸引力的 12.6 倍未来收益和 3.7 倍销售额交易。华尔街仍然看涨，对 INCY 的 12 个月价格目标为 77 美元，暗示着 30% 的上涨潜力。</p>
<h2><strong>Halozyme Therapeutics（HALO）</strong></h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>图片来源：aslysun / Shutterstock.com</p>
<p>我们讨论的备受好评的生物技术股票之一是 Halozyme Theraputics（纳斯达克：HALO），专注于革新药物递送。Halozyme 的核心技术 Enhanze 是一种专利的重组人透明质酸酶，可促进注射生物制剂的皮下递送。Halozyme 的技术有潜力改善各种药物的疗效和耐受性。</p>
<p>五月初，Halozyme 报告了 2024 年第一季度强劲的业绩。收入同比增长 21% 至 1.96 亿美元，受益于持续强劲的 Enhanze 合作伙伴产品和产品线的推进。净收入几乎激增 95% 至 7.68 亿美元，而稀释每股收益激增 68% 至 79 美分。</p>
<p>Halozyme 最近因其 Enhanze 药物递送平台在欧洲获得新专利而提高了 2024 年的财务展望。该专利确保了 Darzelex 在欧洲的原始特许权费率，这是公司的主要收入来源。因此，管理层将 2024 年全年收入指导提高 13% 至 22%，达到 9.35 亿至 10.15 亿美元。</p>
<p>反映这些积极发展，HALO 股票今年迄今已上涨 40%。股票以 12.0 倍未来收益和 8 倍滚动销售额交易。最后，HALO 股票的 12 个月中值预测为 55.50 美元，暗示着 8% 的上涨潜力。</p>
<p><em>在本文发布日期，Tezcan Gecgil 在本文提及的证券中没有（直接或间接）任何持仓。本文中的观点属于作者个人，遵守 InvestorPlace.com 的发布准则。</em></p>
<p><em>在本文发布日期，负责编辑在本文提及的证券中没有（直接或间接）任何持仓。</em></p>
<p>Tezcan Gecgil 博士于 2018 年开始为 InvestorPlace 做出贡献。她在美国和英国拥有超过 20 年的经验，并且已经通过了特许市场技术师（CMT）考试的所有 3 个级别。公开方面，她曾为 investing.com 和 The Motley Fool 英国网站做出贡献。</p>
<p>医疗保健，生物技术</p>
<p>成长股</p>

礼来

<p>医疗保健领域，特别是生物技术领域，正在经历重大进展。FDA 最近批准了礼来新的阿尔茨海默病药物，显示出在减缓认知衰退方面具有希望。拜尔根（Biogen）、英塞特（Incyte）和哈罗泽姆治疗（Halozyme Therapeutics）是三家备受好评的生物技术股，最近获得了监管批准并进行了战略收购。尽管股价表现不佳，这些公司具有强劲的增长潜力。全球生物技术市场预计到 2033 年将达到 4 万亿美元以上</p>

<p>The healthcare sector continues to be a hotbed of innovation, with biotechnology leading the charge. From groundbreaking gene therapies to next-generation cancer treatments, biotech companies are pushing the boundaries of medicine and transforming patient care.</p>
<div class="lb-trans"><p>医疗保健领域继续是创新的热点，生物技术处于领先地位。从开创性的基因疗法到下一代癌症治疗，生物技术公司正在推动医学边界并改变患者护理。</p>
</div><p>This year has already witnessed significant advancements in the biotech space. We’ve seen successful clinical trials, regulatory approvals for life-changing therapies and major acquisitions within the industry. For instance, on July 2, the Food and Drug Administration (FDA) approved <strong>Eli Lilly’s</strong> (NYSE: <strong>LLY</strong>) new Alzheimer’s drug, donanemab, marketed as Kisunla. This drug is designed for patients with early-stage Alzheimer’s disease and has been shown to slow cognitive decline by 29% over 18 months compared to a placebo.</p>
<div class="lb-trans"><p>今年已经见证了生物技术领域的重大进展。我们看到了成功的临床试验，针对改变生活的疗法的监管批准以及行业内的重大收购。例如，7 月 2 日，美国食品药品监督管理局（FDA）批准了礼来（纽约证券交易所：LLY）的新阿尔茨海默病药物，唐纳替普，市场上称为基舜拉。该药物专为早期阿尔茨海默病患者设计，据显示在 18 个月内相对于安慰剂减缓认知衰退 29%。</p>
</div><p>The industry’s growth momentum is expected to continue, fueled by rising investor confidence and a relentless pursuit of scientific breakthroughs. In fact, the global biotechnology market is projected to grow from almost $1.4 trillion in 2023 to well over $4 trillion by 2033, with a compound annual growth rate (CAGR) of 11.8%. North America leads the market, driven by key players, robust R&amp;D and high healthcare spending.</p>
<div class="lb-trans"><p>行业的增长势头预计将继续，受到投资者信心上升和对科学突破的不懈追求的推动。事实上，全球生物技术市场预计将从 2023 年的近 1.4 万亿美元增长到 2033 年的超过 4 万亿美元，复合年增长率（CAGR）为 11.8%。北美市场领先，受关键参与者、强大的研发和高医疗支出推动。</p>
</div><p>It is noteworthy that the <strong>iShares Biotechnology ETF</strong> (NASDAQ: <strong>IBB</strong>) has underperformed the broader market, gaining only 1% YTD. This suggests potential for a catch-up rally within the biotechnology sector. Now, let’s highlight three top-rated biotech stocks that stand out for their recent regulatory approvals, strategic acquisitions and granted patents.</p>
<div class="lb-trans"><p>值得注意的是，iShares 生物技术交易所交易基金（纳斯达克：IBB）表现不佳，年初至今仅上涨 1%。这表明生物技术行业存在迎头赶上的潜力。现在，让我们重点介绍三家备受好评的生物技术股票，因其最近的监管批准、战略收购和授予专利而脱颖而出。</p>
</div><h2><strong>Biogen (BIIB)</strong></h2>
<div class="lb-trans"><h2><strong>Biogen（BIIB）</strong></h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Pavel Kapysh / Shutterstock.com</p>
<div class="lb-trans"><p>图片来源：Pavel Kapysh / Shutterstock.com</p>
</div><p>Topping our list of top-rated biotech stocks is <strong>Biogen</strong>(NASDAQ: <strong>BIIB</strong>), which focuses on complex neurological and neurodegenerative diseases. The company’s product lineup includes treatments for multiple sclerosis (MS), spinal muscular atrophy, plaque psoriasis and Alzheimer’s disease, among others.</p>
<div class="lb-trans"><p>榜首的生物技术股票是 Biogen（纳斯达克：BIIB），专注于复杂的神经系统和神经退行性疾病。该公司的产品线包括治疗多发性硬化症（MS）、脊髓性肌萎缩症、斑块性银屑病和阿尔茨海默病等疾病的治疗。</p>
</div><p>Yet, Biogen’s first quarter 2024 results presented a mixed picture in late April. While total revenue declined 7% year-over-year (YOY) to $2.29 billion, diluted EPS grew 8% to $3.67. This marks a significant milestone, representing the first EPS growth in several years for Biogen.</p>
<div class="lb-trans"><p>然而，Biogen 在 2024 年第一季度的业绩在 4 月底呈现出一幅复杂的画面。尽管总收入同比下降 7% 至 22.9 亿美元，但稀释每股收益增长 8% 至 3.67 美元。这标志着一个重要的里程碑，代表了 Biogen 多年来首次实现的每股收益增长。</p>
</div><p>Biogen has bolstered its presence in two key therapeutic areas with recent regulatory approvals. The European Commission granted marketing authorization for Tofidence, a biosimilar referencing Roactemra for treating various inflammatory diseases. In a separate announcement, Biogen’s collaboration with <strong>Eisai</strong> (OTCMKTS: <strong>ESAIY</strong>) saw the launch of Leqembi (lecanemab) in China. It was the first treatment approved to reduce the progression of Alzheimer’s disease.</p>
<div class="lb-trans"><p>Biogen 通过最近的监管批准加强了在两个关键治疗领域的存在。欧洲委员会授予了 Tofidence 的上市授权，这是一种参考罗氏希罗达治疗各种炎症性疾病的生物类似药。另外，Biogen 与 Eisai（柜台市场：ESAIY）的合作推出了 Leqembi（勒坎替普）在中国的上市。这是首个获批用于减缓阿尔茨海默病进展的治疗。</p>
</div><p>Despite these positive developments, BIIB stock has declined 10% year-to-date (YTD). Currently, Biogen shares are trading at a reasonable 14.3 times forward earnings and 3.5 times sales. Analysts have a 12-month price target of $285.60 for BIIB, signaling 25% upside potential.</p>
<div class="lb-trans"><p>尽管出现这些积极发展，BIIB 股票今年迄今已下跌 10%。目前，Biogen 股票以合理的 14.3 倍未来收益和 3.5 倍销售额交易。分析师对 BIIB 的 12 个月价格目标为 285.60 美元，预示着 25% 的上涨潜力。</p>
</div><h2><strong>Incyte (</strong> INCY)</h2>
<div class="lb-trans"><h2><strong>Incyte（INCY）</strong></h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Eyesonmilan / Shutterstock.com</p>
<div class="lb-trans"><p>图片来源：Eyesonmilan / Shutterstock.com</p>
</div><p>Biopharma company <strong>Incyte</strong>(NASDAQ: <strong>INCY</strong>) specializes in novel small molecule therapies to address unmet medical needs in oncology and inflammatory diseases. Incyte’s product portfolio includes several high-impact drugs like Jakafi, Pemazyre and Iclusig, targeting myelofibrosis, polycythemia vera and chronic myeloid leukemia.</p>
<div class="lb-trans"><p>生物制药公司 Incyte（纳斯达克：INCY）专注于开发新型小分子疗法，以满足肿瘤学和炎症性疾病领域的未满足医疗需求。Incyte 的产品组合包括几种高影响力药物，如 Jakafi、Pemazyre 和 Iclusig，针对骨髓纤维化、红细胞增多症和慢性髓细胞白血病。</p>
</div><p>Incyte reported solid first quarter 2024 results, with total revenues rising 9% YOY to $881 million. Jakafi, their core product for myelofibrosis, maintained its strong performance with net product revenues of $572 million. Net income and diluted EPS both surged around 72% YOY to $145.3 million and 64 cents, respectively.</p>
<div class="lb-trans"><p>Incyte 报告了 2024 年第一季度的强劲业绩，总收入同比增长 9% 至 8.81 亿美元。Jakafi，他们针对骨髓纤维化的核心产品，保持了强劲表现，净产品收入为 5.72 亿美元。净收入和稀释每股收益分别同比激增约 72% 至 1.453 亿美元和 64 美分。</p>
</div><p>Incyte has completed its acquisition of Escient Pharmaceuticals, a company focused on developing novel treatments for systemic immune and neuro-immune disorders. This step is expected to strengthen Incyte’s inflammation and autoimmunity portfolio.</p>
<div class="lb-trans"><p>Incyte 已完成对 Escient Pharmaceuticals 的收购，该公司专注于开发治疗系统性免疫和神经免疫疾病的新型治疗方法。这一举措预计将加强 Incyte 的炎症和自身免疫组合。</p>
</div><p>Despite strong earnings, INCY stock has lost more than 5% so far in 2024. Incyte shares are trading at an attractive 12.6 times forward earnings and 3.7 times sales. Wall Street remains bullish, with a median 12-month price target of $77, implying a 30% upside potential.</p>
<div class="lb-trans"><p>尽管业绩强劲，INCY 股票在 2024 年迄今已下跌超过 5%。Incyte 股票以有吸引力的 12.6 倍未来收益和 3.7 倍销售额交易。华尔街仍然看涨，对 INCY 的 12 个月价格目标为 77 美元，暗示着 30% 的上涨潜力。</p>
</div><h2><strong>Halozyme Therapeutics (HALO)</strong></h2>
<div class="lb-trans"><h2><strong>Halozyme Therapeutics（HALO）</strong></h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: aslysun / Shutterstock.com</p>
<div class="lb-trans"><p>图片来源：aslysun / Shutterstock.com</p>
</div><p>Rounding out our discussion of top-rated biotech stocks is <strong>Halozyme Theraputics</strong>(NASDAQ: <strong>HALO</strong>), focused on revolutionizing drug delivery. Halozyme’s core technology, Enhanze, is a patented recombinant human hyaluronidase enzyme that facilitates the subcutaneous delivery of injectable biologics. Halozyme’s technology has the potential to improve the efficacy and tolerability of a wide range of drugs.</p>
<div class="lb-trans"><p>我们讨论的备受好评的生物技术股票之一是 Halozyme Theraputics（纳斯达克：HALO），专注于革新药物递送。Halozyme 的核心技术 Enhanze 是一种专利的重组人透明质酸酶，可促进注射生物制剂的皮下递送。Halozyme 的技术有潜力改善各种药物的疗效和耐受性。</p>
</div><p>In early May, Halozyme reported strong first quarter 2024 earnings. Revenue increased 21% YOY to $196 million driven by continued strong advancement of Enhanze partner products and pipeline. Net income skyrocketed almost 95% to $76.8 million, while diluted EPS surged 68% to 79 cents.</p>
<div class="lb-trans"><p>五月初，Halozyme 报告了 2024 年第一季度强劲的业绩。收入同比增长 21% 至 1.96 亿美元，受益于持续强劲的 Enhanze 合作伙伴产品和产品线的推进。净收入几乎激增 95% 至 7.68 亿美元，而稀释每股收益激增 68% 至 79 美分。</p>
</div><p>Halozyme recently raised its financial outlook for 2024 following the grant of a new European patent for its Enhanze drug delivery platform. This patent secures the original royalty rate for Darzelex in Europe, a key revenue driver for the company. As a result, management raised its full-year 2024 revenue guidance 13% to 22% YOY to $935 million to $1.015 billion.</p>
<div class="lb-trans"><p>Halozyme 最近因其 Enhanze 药物递送平台在欧洲获得新专利而提高了 2024 年的财务展望。该专利确保了 Darzelex 在欧洲的原始特许权费率，这是公司的主要收入来源。因此，管理层将 2024 年全年收入指导提高 13% 至 22%，达到 9.35 亿至 10.15 亿美元。</p>
</div><p>Reflecting the positive developments, HALO stock has appreciated 40% YTD. The shares are trading at 12.0 times forward earnings and 8 times trailing sales. Finally, the 12-month median forecast for HALO stock stands at $55.50, suggesting an 8% upside potential.</p>
<div class="lb-trans"><p>反映这些积极发展，HALO 股票今年迄今已上涨 40%。股票以 12.0 倍未来收益和 8 倍滚动销售额交易。最后，HALO 股票的 12 个月中值预测为 55.50 美元，暗示着 8% 的上涨潜力。</p>
</div><p><em>On the date of publication, Tezcan Gecgil did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.</em></p>
<div class="lb-trans"><p><em>在本文发布日期，Tezcan Gecgil 在本文提及的证券中没有（直接或间接）任何持仓。本文中的观点属于作者个人，遵守 InvestorPlace.com 的发布准则。</em></p>
</div><p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div class="lb-trans"><p><em>在本文发布日期，负责编辑在本文提及的证券中没有（直接或间接）任何持仓。</em></p>
</div><p>Tezcan Gecgil, PhD, began contributing to InvestorPlace in 2018. She brings over 20 years of experience in the U.S. and U.K. and has also completed all 3 levels of the Chartered Market Technician (CMT) examination. Publicly, she has contributed to investing.com and the U.K. website of The Motley Fool.</p>
<div class="lb-trans"><p>Tezcan Gecgil 博士于 2018 年开始为 InvestorPlace 做出贡献。她在美国和英国拥有超过 20 年的经验，并且已经通过了特许市场技术师（CMT）考试的所有 3 个级别。公开方面，她曾为 investing.com 和 The Motley Fool 英国网站做出贡献。</p>
</div><p>Healthcare, Biotech</p>
<div class="lb-trans"><p>医疗保健，生物技术</p>
</div><p>Growth Stocks</p>
<div class="lb-trans"><p>成长股</p>
</div>

3 只高评级的生物科技股票，适合纳入您的七月购买清单